RATIONALE: The course of lung function decline for smokers with early airflow obstruction remains undefined. It is also unclear which early spirometric characteristics identify individuals at risk for rapid decline and increased mortality. OBJECTIVES: To determine the association between spirometric measures and 5-year decline in FEV(1) and 12-year mortality. METHODS: We analyzed longitudinal data from the Lung Health Study, a clinical trial of intensive smoking cessation intervention with or without bronchodilator therapy in 5,887 smokers with mild to moderate airflow obstruction. Participants were stratified into bins of baseline FEV(1) to FVC ratio, using bins of 5%, and separately into bins of Z-score (difference between actual and predicted FEV(1)/FVC, normalized to SD of predicted FEV(1)/FVC). Associations between spirometric measures and FEV(1) decline and mortality were determined after adjusting for baseline characteristics and time-varying smoking status. MEASUREMENTS AND MAIN RESULTS: The cohort was approximately two-thirds male, predominantly of white race (96%), and with mean age of 49 ± 7 years. In general, individuals with lower lung function by any metric had more rapid adjusted FEV(1) decline. A threshold for differential decline was present at FEV(1)/FVC less than 0.65 (P < 0.001) and Z-score less than -2 (2.3 percentile) (P < 0.001). At year 12, 575 (7.2%) of the cohort had died. Lower thresholds of each spirometric metric were associated with increasing adjusted hazard of death. CONCLUSIONS: Smokers at risk or with mild to moderate chronic obstructive pulmonary disease have accelerated lung function decline. Individuals with lower baseline FEV(1)/FVC have more rapid decline and worse mortality.
RATIONALE: The course of lung function decline for smokers with early airflow obstruction remains undefined. It is also unclear which early spirometric characteristics identify individuals at risk for rapid decline and increased mortality. OBJECTIVES: To determine the association between spirometric measures and 5-year decline in FEV(1) and 12-year mortality. METHODS: We analyzed longitudinal data from the Lung Health Study, a clinical trial of intensive smoking cessation intervention with or without bronchodilator therapy in 5,887 smokers with mild to moderate airflow obstruction. Participants were stratified into bins of baseline FEV(1) to FVC ratio, using bins of 5%, and separately into bins of Z-score (difference between actual and predicted FEV(1)/FVC, normalized to SD of predicted FEV(1)/FVC). Associations between spirometric measures and FEV(1) decline and mortality were determined after adjusting for baseline characteristics and time-varying smoking status. MEASUREMENTS AND MAIN RESULTS: The cohort was approximately two-thirds male, predominantly of white race (96%), and with mean age of 49 ± 7 years. In general, individuals with lower lung function by any metric had more rapid adjusted FEV(1) decline. A threshold for differential decline was present at FEV(1)/FVC less than 0.65 (P < 0.001) and Z-score less than -2 (2.3 percentile) (P < 0.001). At year 12, 575 (7.2%) of the cohort had died. Lower thresholds of each spirometric metric were associated with increasing adjusted hazard of death. CONCLUSIONS: Smokers at risk or with mild to moderate chronic obstructive pulmonary disease have accelerated lung function decline. Individuals with lower baseline FEV(1)/FVC have more rapid decline and worse mortality.
Authors: N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara Journal: JAMA Date: 1994-11-16 Impact factor: 56.272
Authors: Christine R Jenkins; Paul W Jones; Peter M A Calverley; Bartolome Celli; Julie A Anderson; Gary T Ferguson; Julie C Yates; Lisa R Willits; Jörgen Vestbo Journal: Respir Res Date: 2009-06-30
Authors: W M Vollmer; Thorn Gíslason; P Burney; P L Enright; A Gulsvik; A Kocabas; A S Buist Journal: Eur Respir J Date: 2009-05-21 Impact factor: 16.671
Authors: Nirupama Putcha; M Bradley Drummond; John E Connett; Paul D Scanlon; Donald P Tashkin; Nadia N Hansel; Robert A Wise Journal: COPD Date: 2013-10-15 Impact factor: 2.409
Authors: Katja Hueper; Jens Vogel-Claussen; Megha A Parikh; John H M Austin; David A Bluemke; James Carr; Jiwoong Choi; Thomas A Goldstein; Antoinette S Gomes; Eric A Hoffman; Steven M Kawut; Joao Lima; Erin D Michos; Wendy S Post; Ming Jack Po; Martin R Prince; Kiang Liu; Dan Rabinowitz; Jan Skrok; Ben M Smith; Karol Watson; Youbing Yin; Alan M Zambeli-Ljepovic; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Kathleen A Clark; Wilfried J J Karmaus; Lawrence C Mohr; Bo Cai; Pallavi Balte; James J Gibson; Dennis Ownby; Andrew B Lawson; John E Vena; Erik R Svendsen Journal: Ann Am Thorac Soc Date: 2016-03
Authors: Mengling Liu; Meng Qian; Qinyi Cheng; Kenneth I Berger; Yongzhao Shao; Meredith Turetz; Angeliki Kazeros; Sam Parsia; Roberta M Goldring; Caraleess Caplan-Shaw; Maria Elena Fernandez-Beros; Michael Marmor; Joan Reibman Journal: J Occup Environ Med Date: 2012-10 Impact factor: 2.162
Authors: Michael A Thomashow; Daichi Shimbo; Megha A Parikh; Eric A Hoffman; Jens Vogel-Claussen; Katja Hueper; Jessie Fu; Chia-Ying Liu; David A Bluemke; Corey E Ventetuolo; Margaret F Doyle; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405
Authors: Juan Jose Carmona; Richard T Barfield; Tommaso Panni; Jamaji C Nwanaji-Enwerem; Allan C Just; John N Hutchinson; Elena Colicino; Stefan Karrasch; Simone Wahl; Sonja Kunze; Nadereh Jafari; Yinan Zheng; Lifang Hou; Dawn L DeMeo; Augusto A Litonjua; Pantel S Vokonas; Annette Peters; Xihong Lin; Joel Schwartz; Holger Schulz; Andrea A Baccarelli Journal: Epigenetics Date: 2018-10-21 Impact factor: 4.528